BNT327 + Chemotherapy for Lung Cancer

Recruiting at 67 trial locations

Overseen By BioNTech clinical trials patient information

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: BioNTech SE

Must not be taking: Corticosteroids, Antibiotics, Immunotherapy, others

Disqualifiers: Pregnancy, Autoimmune diseases, Heart conditions, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: up to 2 years

110 Participants Needed

Trial Summary

What is the purpose of this trial?

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.

Do I need to stop my current medications to join the trial?

The protocol does not specify if you need to stop your current medications. However, certain treatments like systemic corticosteroids, live vaccines, and some antibiotics must be stopped within specific timeframes before starting the trial. It's best to discuss your current medications with the trial team.

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, certain treatments, like systemic corticosteroids above a specific dose and some recent therapies, are not allowed before starting the study. It's best to discuss your current medications with the study team to see if any adjustments are needed.

What data supports the idea that BNT327 + Chemotherapy for Lung Cancer (also known as: BNT327, PM8002) is an effective treatment?

The available research shows that while new chemotherapy agents have been developed for non-small cell lung cancer (NSCLC), they only offer modest benefits, such as slightly longer survival and improved quality of life. There is no specific data on BNT327 + Chemotherapy for Lung Cancer in the provided information, but it suggests that new treatments are needed to improve outcomes. Other treatments like targeted therapies are being explored to enhance the effectiveness of chemotherapy. Therefore, while BNT327 + Chemotherapy might be promising, the data provided does not specifically support its effectiveness over other treatments. ^{1 2 3 4 5}

What data supports the effectiveness of the drug BNT327 + Chemotherapy for lung cancer?

The research highlights that new chemotherapy agents, including those similar to BNT327, have shown promise in treating non-small cell lung cancer (NSCLC) by modestly improving survival and quality of life. Although traditional chemotherapy has reached a plateau in effectiveness, novel targeted therapies are emerging as a new approach to improve outcomes in NSCLC treatment. ^{1 2 3 4 5}

What safety data exists for BNT327 + Chemotherapy in lung cancer treatment?

The provided research does not contain specific safety data for BNT327 or PM8002 in combination with chemotherapy for lung cancer. The studies focus on other agents and combinations, such as ABT-751 with carboplatin, and do not mention BNT327 or PM8002. Therefore, no relevant safety data for BNT327 + Chemotherapy is available in the provided research. ^{6 7 8 9 10}

Is the drug BNT327 (PM8002) a promising treatment for lung cancer?

Yes, BNT327 (PM8002) is a promising drug for lung cancer because new treatments like it are being developed to improve survival and quality of life for patients. These new drugs target specific parts of cancer cells, offering hope for better outcomes compared to older treatments. ^{1 2 3 7 11}

What makes the drug BNT327 unique for lung cancer treatment?

BNT327 (PM8002) is unique because it represents a novel approach in lung cancer treatment, potentially offering a new mechanism of action compared to traditional chemotherapy drugs, which have reached a plateau in efficacy. This drug may target specific pathways in cancer cells, providing a more focused treatment option. ^{1 2 3 7 11}

Research Team

BioNTech Responsible Person

Principal Investigator

BioNTech SE

Eligibility Criteria

This trial is for adults with untreated extended-stage small-cell lung cancer (ES-SCLC) or those whose SCLC has worsened after treatment. Participants must have a life expectancy over 3 months, an adequate neutrophil count, and at least one measurable lesion. Prior therapy recipients are eligible if they've had a 6-month break before ES-SCLC diagnosis.

Inclusion Criteria

I can follow the study's schedule and requirements.

I have signed the consent form for this study.

I have at least one tumor that can be measured and has not been treated locally.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive BNT327 in combination with chemotherapy until disease progression, intolerable toxicity, patient withdrawal, study termination, or up to 2 years

up to 2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

up to 24 months after completion of study treatment

Treatment Details

Interventions

• BNT327

Trial Overview The study tests BNT327's safety and preliminary effectiveness in combination with chemotherapy drugs like Topoisomerase Inhibitors A & B, Taxane, and Alkylating agents. It includes patients who haven't been treated yet as well as those who've seen their cancer progress post-treatment.

Participant Groups

Group I: Cohort 3 Arm 2 - BNT327 DL2 + topotecan Experimental Treatment 2 Interventions

Participants with SCLC who have disease progression/relapse

Group II: Cohort 3 Arm 1 - BNT327 DL1 + topotecan Experimental Treatment 2 Interventions

Participants with SCLC who have disease progression/relapse

Group III: Cohort 2 Arm 2 - BNT327 DL2 + paclitaxel Experimental Treatment 2 Interventions

Participants with SCLC who have disease progression/relapse

Group IV: Cohort 2 Arm 1 - BNT327 DL1 + paclitaxel Experimental Treatment 2 Interventions

Participants with SCLC who have disease progression/relapse

Group V: Cohort 1 Arm 2 - BNT327 DL2 + carboplatin + etoposide Experimental Treatment 3 Interventions

Participants with ES-SCLC without prior systemic anticancer therapy received in the ES setting

Group VI: Cohort 1 Arm 1 - BNT327 DL1 + carboplatin + etoposide Experimental Treatment 3 Interventions

Participants with ES-SCLC without prior systemic anticancer therapy received in the ES setting

Who Is Running the Clinical Trial?

BioNTech SE

Lead Sponsor

Trials

84

Recruited

120,000+

Prof. Dr. Ugur Sahin

BioNTech SE

Chief Executive Officer since 2008

MD from University of Cologne

Prof. Özlem Türeci

BioNTech SE

Chief Medical Officer since 2018

MD from Saarland University

Findings from Research

A variety of new agents, including taxanes, gemcitabine, and irinotecan, have shown promise in early clinical studies for treating non-small-cell lung cancer (NSCLC), indicating potential for improved treatment options.

Cisplatin remains a key component in combination therapies for NSCLC, being tested alongside these new agents, radiation, and surgery in numerous trials to enhance treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Chemotherapy in metastatic non-small-cell lung cancer. Sandler, A.[2022]

Recent meta-analysis indicates that while alkylating agents negatively impact survival in non-small cell lung cancer (NSCLC), cisplatin-containing regimens provide a modest survival benefit.

The review highlights several promising cytotoxic agents, such as vinorelbine and docetaxel, which show potential for improving treatment outcomes in advanced NSCLC, emphasizing the need for new drug development.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer]. Masuda, N.[2022]

Cytotoxic chemotherapy for advanced non-small cell lung cancer (NSCLC) provides only limited benefits, such as modest survival prolongation and symptom relief, compared to best supportive care alone.

There is a need for new treatment approaches, as traditional chemotherapy has reached a plateau in efficacy and safety; targeted therapies that focus on specific cancer cell pathways may offer a promising alternative for improving NSCLC treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Targeted therapy in non-small cell lung cancer. Giaccone, G.[2019]

Only a few traditional chemotherapeutic agents have shown single-agent response rates greater than 15% in treating non-small-cell lung cancer (NSCLC), indicating limited effectiveness with standard treatments.

Recent phase I/II trials have identified new drugs, such as navelbine, CTP-11, topotecan, and taxol, that have achieved single-agent response rates above 20%, suggesting improved treatment options for NSCLC patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New directions for chemotherapy in non-small-cell lung cancer. Green, MR.[2019]

Recent advancements in targeted therapies for advanced non-small cell lung cancer have shown promise, with agents like docetaxel, pemetrexed, and erlotinib undergoing phase III trials to assess their effectiveness after previous treatments.

The review emphasizes the importance of identifying predictors of favorable outcomes to guide treatment selection, highlighting ongoing pivotal trials that may shape future strategies in managing this type of lung cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Optimizing therapy in previously treated non-small cell lung cancer. Miller, VA.[2018]

The combination of ABT-751 and carboplatin significantly reduced lung cancer cell growth and induced cell death in preclinical studies, suggesting a potential effective treatment strategy.

In a phase I study with 20 advanced NSCLC patients, the maximum tolerated dose was determined to be ABT-751 125 mg twice daily, with modest clinical activity observed, including a median overall survival of 11.7 months and two confirmed partial responses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Ma, T., Fuld, AD., Rigas, JR., et al.[2021]

Current standard treatment for advanced non-small-cell lung cancer involves doublet chemotherapy, which has shown 1-year survival rates of approximately 35% and 2-year survival rates of about 15%.

Preliminary studies indicate that triplet therapy may enhance survival rates compared to double therapy, with toxicity rates being low enough to support the development of these three-drug combinations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Triplet combination chemotherapy and targeted therapy regimens. Bunn, PA.[2005]

In a study involving 15 patients with advanced non-small cell lung cancer (NSCLC) who had previously undergone chemotherapy, the novel antitumor agent MGI-114 showed no objective tumor responses, leading to the conclusion that it is not effective as a second-line treatment.

The treatment was associated with significant side effects, including grade 2 or higher thrombocytopenia in 40% of patients, and grade 3 nausea and grade 2 vomiting in 40% and 47% of patients, respectively, indicating safety concerns with this dosing regimen.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy. Dowell, JE., Johnson, DH., Rogers, JS., et al.[2019]

In a phase II trial involving 51 patients with metastatic non-small-cell lung cancer (NSCLC), VP-16-213 showed a low overall response rate of only 4%, with partial responses occurring exclusively in previously untreated patients.

The treatment was associated with significant side effects, including myelosuppression and two drug-related deaths from septicemia, indicating that while it has minimal efficacy, it also poses safety risks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II trial of VP-16-213 in non-small-cell lung cancer. Itri, LM., Gralla, RJ., Chapman, RA., et al.[2013]

Lung cancer remains the leading cause of cancer-related deaths in the U.S. for individuals over 35, highlighting the urgent need for more effective treatments beyond standard chemotherapy.

Several new agents, including paclitaxel and gemcitabine, have demonstrated significant effectiveness in treating non-small cell lung cancer, suggesting promising avenues for future research and development.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New Agents in Non-Small Cell Lung Cancer. Feigal, EG.[2019]

Platinum-containing doublet chemotherapy combinations have become the standard treatment for advanced non-small cell lung cancer (NSCLC), showing a survival advantage for patients diagnosed at later stages.

Recent studies indicate that nonplatinum combinations and the addition of bevacizumab to existing regimens can further improve patient outcomes, while ongoing research is exploring maintenance therapies and second-line treatments like docetaxel and pemetrexed for refractory cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Chemotherapy for advanced stage non-small cell lung cancer. Fathi, AT., Brahmer, JR.[2008]

References

1. United States pubmed.ncbi.nlm.nih.gov

Chemotherapy in metastatic non-small-cell lung cancer. [2022]

2. Japan pubmed.ncbi.nlm.nih.gov

[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer]. [2022]

3. Ireland pubmed.ncbi.nlm.nih.gov

Targeted therapy in non-small cell lung cancer. [2019]

4. United States pubmed.ncbi.nlm.nih.gov

New directions for chemotherapy in non-small-cell lung cancer. [2019]

5. United States pubmed.ncbi.nlm.nih.gov

Optimizing therapy in previously treated non-small cell lung cancer. [2018]

6. Switzerland pubmed.ncbi.nlm.nih.gov

A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. [2021]

7. United States pubmed.ncbi.nlm.nih.gov

Triplet combination chemotherapy and targeted therapy regimens. [2005]

8. United States pubmed.ncbi.nlm.nih.gov

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy. [2019]

9. United States pubmed.ncbi.nlm.nih.gov

Phase II trial of VP-16-213 in non-small-cell lung cancer. [2013]

10. United States pubmed.ncbi.nlm.nih.gov

New Agents in Non-Small Cell Lung Cancer. [2019]

11. United States pubmed.ncbi.nlm.nih.gov

Chemotherapy for advanced stage non-small cell lung cancer. [2008]